NCT04202978

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer: One-arm Exploratory Clinical Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: Zhongshan Hospital Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation

Detailed description

To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation. The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously every 3weeks and 250mg apatinib mesylate qd ，and 850mg/m2 capecitabine d1-14 and 130mg/m2 oxaliplatin given intravenously d1.

Conditions

• Hepatic Metastasis of Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab ：200mg intravenous injection d1 q3w
DRUG	Apatinib Mesylate	Apatinib：250mg/d P.O ,qd ,3weeks
DRUG	Capecitabine	capecitabine:850mg/m2 P.O ,bid ,d1-d14
DRUG	Oxaliplatin	oxaliplatin:130mg/m2 intravenous injection d1 q3w
RADIATION	radiofrequency ablation	radiofrequency ablation:between first cycle and second cycle percutaneous

Timeline

• Start date: 2020-03-01
• Primary completion: 2021-03-01
• Completion: 2021-11-01
• First posted: 2019-12-18
• Last updated: 2020-04-16

Locations

1 site across 1 country: China